Lindsey Shapiro, PhD, science writer —

Anumana’s electrocardiogram (ECG)-based algorithm for the early detection of pulmonary hypertension (PH) has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). Developed through a collaboration of scientists at Anumana, Janssen Research and Development, and the Mayo Clinic, the artificial intelligence (AI)-powered algorithm is designed…

To celebrate World Pulmonary Hypertension Day on May 5, Ferrer and the European Pulmonary Hypertension Association (PHA Europe) have launched the PHantasticals campaign to raise public awareness about rare and chronic lung diseases like pulmonary hypertension (PH). The campaign features a collection of mermaid characters called the…

Chiesi Farmaceutici has acquired the worldwide rights to a number of investigational antibodies that may be able to treat pulmonary arterial hypertension (PAH) from the developer, Allinaire Therapeutics. All of the antibodies act against the endothelial monocyte-activating polypeptide (EMAP II), a pro-inflammatory molecule that is thought to…

Longer-term use of Ventavis (iloprost) as an add-on therapy significantly improved blood flow and lowered blood pressure in people with pulmonary arterial hypertension (PAH), a small study in Japan reported. Findings support this inhaled therapy’s established benefits as a pulmonary vasodilator — a medicine that  widens, or dilate,…

Infants born extremely premature — at 23 to 25 weeks of pregnancy — are at a high risk of developing pulmonary hypertension (PH) before they are 3 months old but can be helped with treatment, a recent study reported. Initial signs of disease, evident on echocardiographs in these infants,…

The Pulmonary Hypertension Association (PHA) will join more than 80 organizations around the world on May 5 to recognize World Pulmonary Hypertension (PH) Day. The event is intended to raise global awareness about PH, a rare, life-threatening disease that affects more than 75 million people worldwide and for which…

Treatment with DehydraTECH-CBD, Lexaria Bioscience’s investigational cannabis-derived treatment for pulmonary hypertension (PH), led to reduced pulmonary artery pressure in healthy volunteers who were exposed to low oxygen levels — especially among male participants — in conditions that mimicked PH. This was according to data from the now-completed HYPER-H21-3…

A four-week self-help intervention program — based on principles of cognitive-behavioral therapy (CBT), a type of talk therapy — significantly reduced anxiety and depression among people with pulmonary hypertension (PH), according to data from a small U.K. pilot study. “We developed a self-help intervention for anxiety in PH, which…

The Pulmonary Hypertension Association (PHA) is accepting nominations for its Outstanding Member Awards, which recognize individuals who show dedication to the pulmonary hypertension (PH) community. People with PH, their caregivers, friends, and doctors are invited to nominate “outstanding” PHA members for their “volunteer efforts in patient/caregiver support, advocacy,…

Markers of a type of blood cell called a platelet — the blood cells involved in blood clotting after injury — were associated with disease severity and heart dysfunction in children with pulmonary arterial hypertension (PAH) and congenital heart disease (CHD), according to a recent study These findings show…

Higher blood levels of hepatoma-derived growth factor (HDGF), involved in blood vessel remodeling, associated with greater disease severity and mortality risk in pulmonary arterial hypertension (PAH) patients in a large biobank study. Based on additional work in a rat model, its researchers suggested these outcomes were due to the factor’s…

The short-term survival rate of patients with both human immunodeficiency virus (HIV) and pulmonary arterial hypertension (PAH) — dubbed HIV-PAH — is similar to that of people with idiopathic or familial forms of PAH, according to the results of a Spanish study spanning 20 years. Patients with HIV-PAH also…